Want to see AU:PYC full AI Analyst Report?
Top Page
PYC Therapeutics Limited
(Sydney:PYC)
Select Model
Select Model
Rating:51Neutral
Price Target:
AU$1.50
▲(17.19% Upside)
Action:Reiterated
Date:11/25/25
PYC Therapeutics Limited's stock score is primarily impacted by its financial challenges, including declining revenues and persistent losses. While technical analysis indicates a positive trend, the valuation remains unattractive due to a negative P/E ratio and no dividend yield. The lack of earnings call data and corporate events further limits the assessment.
Positive Factors
RNA-based therapeutic platform
PYC's RNA-focused platform is a durable strategic asset: targeting RNA allows modulation of gene expression across multiple genetic conditions, enabling a scalable pipeline approach. This platform-driven model supports repeatable R&D leverage, potential partner interest, and long-term program expansion across indications.
Negative Factors
Declining revenues
Sustained revenue decline undermines internal funding for costly clinical programs and signals weakening commercial traction or milestone receipts. Over a multi-month horizon this trend compresses runway, increases dependency on external capital, and can constrain investment in pipeline breadth and strategic partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
RNA-based therapeutic platform
PYC's RNA-focused platform is a durable strategic asset: targeting RNA allows modulation of gene expression across multiple genetic conditions, enabling a scalable pipeline approach. This platform-driven model supports repeatable R&D leverage, potential partner interest, and long-term program expansion across indications.
Read all positive factors
PYC Therapeutics Limited (PYC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$1.66B
Dividend YieldN/A
Average Volume (3M)499.42K
Price to Earnings (P/E)―
Beta (1Y)1.67
Revenue GrowthN/A
EPS Growth22.52%
CountryAU
Employees37
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.09
Shares Outstanding983,510,440
10 Day Avg. Volume237,599
30 Day Avg. Volume499,416
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)3.84
Price to Sales (P/S)27.69
P/FCF Ratio-12.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$2.84Price Target Upside121.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.08
Revenue Forecast (FY)AU$5.00M
PYC Therapeutics Limited Business Overview & Revenue Model
Company Description
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical tr...
How the Company Makes Money
null...
PYC Therapeutics Limited Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.66M | 23.49M | 22.06M | 15.81M | 16.04M | 3.07M |
| Gross Profit | 11.35M | 23.49M | 22.06M | 14.92M | 15.20M | 2.45M |
| EBITDA | -59.80M | -52.88M | -54.55M | -38.25M | -29.39M | -21.04M |
| Net Income | -47.56M | -50.30M | -37.73M | -22.79M | -13.86M | -17.77M |
Balance Sheet | ||||||
| Total Assets | 159.13M | 183.28M | 91.24M | 37.17M | 45.35M | 57.94M |
| Cash, Cash Equivalents and Short-Term Investments | 120.69M | 153.05M | 66.87M | 15.57M | 29.11M | 51.50M |
| Total Debt | 1.26M | 1.02M | 1.11M | 315.49K | 943.77K | 730.35K |
| Total Liabilities | 11.80M | 13.27M | 10.18M | 8.72M | 5.15M | 4.02M |
| Stockholders Equity | 147.18M | 169.57M | 80.50M | 27.75M | 39.35M | 53.04M |
Cash Flow | ||||||
| Free Cash Flow | -66.22M | -52.54M | -38.90M | -24.91M | -22.17M | -12.38M |
| Operating Cash Flow | -65.75M | -51.56M | -38.59M | -24.42M | -21.78M | -11.79M |
| Investing Cash Flow | -463.80K | -975.40K | -307.04K | -477.12K | 32.68M | -15.52M |
| Financing Cash Flow | 138.63M | 138.66M | 90.19M | 11.44M | -182.36K | 38.56M |
PYC Therapeutics Limited Technical Analysis
Positive
1.28
Price Trends
1.34
Positive
1.35
Positive
1.34
Positive
Market Momentum
0.07
Negative
69.25
Neutral
87.55
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PYC, the sentiment is Positive. The current price of 1.28 is below the 20-day moving average (MA) of 1.38, below the 50-day MA of 1.34, and below the 200-day MA of 1.34, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 69.25 is Neutral, neither overbought nor oversold. The STOCH value of 87.55 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:PYC.
PYC Therapeutics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$2.25B | 73.96 | 9.20% | ― | -69.69% | -78.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$1.66B | -19.94 | -30.03% | ― | ― | 22.52% | |
47 Neutral | AU$294.65M | -90.91 | -15.96% | ― | 364.97% | 74.50% | |
45 Neutral | AU$798.16M | -7.64 | -59.59% | ― | ― | -70.72% | |
41 Neutral | AU$117.12M | -3.58 | 279.21% | ― | ― | -37.23% | |
39 Underperform | AU$20.52M | -3.08 | 44.23% | ― | -98.07% | ― |
* Healthcare Sector Average
AU:PYC
PYC Therapeutics Limited
1.69
0.42
33.31%
AU:OPT
Opthea
0.02
-0.59
-97.50%
AU:NEU
Neuren Pharmaceuticals Limited
17.75
3.50
24.56%
AU:SPL
Starpharma Holdings Limited
0.70
0.61
704.60%
AU:CU6
Clarity Pharmaceuticals Ltd.
2.14
-0.56
-20.74%
AU:RCE
Recce Pharmaceuticals Ltd.
0.41
0.12
42.11%
PYC Therapeutics Limited Corporate Events
PYC Therapeutics Announces Lapse of 700,000 Unlisted Options
Jun 17, 2026
PYC Therapeutics Limited has reported the lapse of 700,000 unlisted options, comprising 400,000 options exercisable at $3.00 expiring in November 2028 and 300,000 options exercisable at $2.52 expiring in January 2029. The options ceased to exist o...
PYC Therapeutics Resets CEO Pay to Sharpen Market Alignment and Performance Focus
May 26, 2026
PYC Therapeutics has revised the remuneration package for its Chief Executive Officer, Dr. Rohan Hockings, following an independent review aimed at aligning pay with market practices and reflecting the CEO’s role in building long-term shareh...
PYC Therapeutics outlines limits of data and risk profile in investor update
May 22, 2026
PYC Therapeutics has released an investor presentation intended to update shareholders on its business and development pipeline, while stressing that the slides are only an aid and must be read alongside its formal market announcements. The compan...
PYC Therapeutics Cuts Option Overhang as Multiple Incentive Securities Lapse
May 11, 2026
PYC Therapeutics Limited has reported the cessation of several tranches of employee and incentive options listed on the ASX, with exercise prices primarily at $1.70 and one at $0.90. These options, expiring between 2026 and 2031, have either lapse...
PYC to unveil early clinical data on first-in-class gene-targeted eye drugs at ARVO
May 3, 2026
PYC Therapeutics will showcase data from its Phase 1/2 clinical trials for two lead ophthalmology candidates, VP-001 for Retinitis Pigmentosa type 11 and PYC-001 for Autosomal Dominant Optic Atrophy, at the ARVO conference in Denver from 3 to 7 Ma...
PYC Therapeutics Issues New Shares Following Option Exercise and Lodges Cleansing Notice
Apr 28, 2026
PYC Therapeutics has issued 250,000 fully paid ordinary shares following the exercise of an equivalent number of unlisted options priced at $0.90 each, with an expiry date in October 2027. The new shares are being quoted on the ASX, modestly incre...
PYC Therapeutics Lists Additional 250,000 Shares on ASX
Apr 28, 2026
PYC Therapeutics has applied for quotation on the ASX of 250,000 new ordinary fully paid shares, with an issue date of April 28, 2026. The additional securities, arising from the exercise or conversion of existing instruments, will modestly expand...
PYC Therapeutics Advances Genetic Disease Pipeline After $600m Capital Raise
Apr 27, 2026
PYC Therapeutics reported significant first-quarter 2026 progress across its precision medicine pipeline for genetic diseases with no existing treatments. The company advanced all four development programs toward near-term goals, underscoring its ...
PYC Wins EMA Orphan Status for RP11 Gene Therapy Candidate VP-001
Apr 27, 2026
PYC Therapeutics has secured Orphan Drug Designation from the European Medicines Agency for VP-001, its investigational therapy for Retinitis Pigmentosa type 11, a rare blinding eye disease with no approved treatments. The status provides 10 years...
PYC Therapeutics Wins Safety Nod to Advance ADOA Drug PYC-001 to Multi-Dose Trial
Apr 15, 2026
PYC Therapeutics has reported that the Safety Review Committee overseeing its Phase 1 Single Ascending Dose trial of PYC-001 in Autosomal Dominant Optic Atrophy has reviewed four-week safety and tolerability data at the 60 microgram dose. The comm...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.